Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer

15 November 1984

journal article
research article
Published by Massachusetts Medical Society in New England Journal of Medicine

Vol. 311 (20) , 1281-1286
https://doi.org/10.1056/nejm198411153112004

Abstract

We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment.

This publication has 28 references indexed in Scilit:

THERAPEUTIC POTENTIAL OF THE LHRH AGONIST, ICI 118630, IN THE TREATMENT OF ADVANCED PROSTATIC CARCINOMA
The Lancet, 1983
TREATMENT OF ADVANCED PROSTATIC CANCER WITH LHRH ANALOGUE ICI 118630: CLINICAL RESPONSE AND HORMONAL MECHANISMS
The Lancet, 1983
Gonadotropin‐releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma
The Prostate, 1982
Short-Term Treatment of Idiopathic Precocious Puberty with a Long-Acting Analogue of Luteinizing Hormone-Releasing Hormone
New England Journal of Medicine, 1981
Reversible Inhibition of Testicular Steroidogenesis and Spermatogenesis by a Potent Gonadotropin-Releasing Hormone Agonist in Normal Men
New England Journal of Medicine, 1981
THERAPEUTIC USE OF PITUITARY OESENSITIZATION WITH A LONG-ACTING LHRM AGONIST: A POTENTIAL NEW TREATMENT FOR IDIOPATHIC PRECOCIOUS PUBERTY*
Journal of Clinical Endocrinology & Metabolism, 1981
INTRANASAL GONADOTROPIN-RELEASING HORMONE AGONIST AS A CONTRACEPTIVE AGENT
The Lancet, 1979
Hypophysial Responses to Continuous and Intermittent Delivery of Hypothalamic Gonadotropin-Releasing Hormone
Science, 1978
Studies on Prostatic Cancer. III. The Effects of Fever, of Desoxycorticosterone and of Estrogen on Clinical Patients with Metastatic Carcinoma of the Prostate ^,
Journal of Urology, 1941
STUDIES ON PROSTATIC CANCER
Archives of Surgery, 1941